Results 81 to 90 of about 1,181,836 (211)

A Critical Look at Innovation Profile and Its Relationship with Pharmaceutical Industry [PDF]

, 2017
Background: The pharmaceutical sector undertakes extensive research and development (R&D). Pharmaceutical industries have continued to launch an appreciable number of new medicines, different pharmaceutical formulations, new indications and other ...
Acurcio, FdeA, Dias, CZ, Dias, EM, Godman, B, Guerra Jnr, AA, Martin, A, Prata, WM, Silvestre, RG   +7 more
core   +1 more source

Biosimilar Infliximab (CT-P13 Remsima™) Is Effective in The Healing of Fistulizing Crohn’s Disease [PDF]

Journal of Surgery, 2017
n ...
Romano, Marco, Ferrante, Emanuele, Romano, Lorenzo, Sgambato, Dolores, Miranda, Agnese, Maurea, Simone, de Sio, Ilario, Mollica, Carmine, Romeo, Valeria, De Musis, Cristiana   +9 more
openaire   +1 more source

Nicotine pouches and clinical outcomes related to smoking cessation: A systematic review of randomized trials

Addiction, EarlyView.
Abstract Background and aims Tobacco‐free nicotine pouches (NPs) are oral nicotine products promoted by manufacturers and some researchers as tools that may reduce nicotine cravings and support smoking reduction or cessation. However, evidence regarding their actual clinical impact remains limited.
Javad Heshmati, Spencer Shahen, Emma Lynn Bates, Sarah Visintini, Evyanne Quirouette, Kerri‐Anne Mullen, Hassan Mir   +6 more
wiley   +1 more source

Long-term follow up after switching from original infliximab to an infliximab biosimilar: real-world data

Therapeutic Advances in Gastroenterology, 2019
Background: Several studies have reported positive efficacy outcomes for patients with inflammatory bowel disease treated with CT-P13, an infliximab biosimilar. Data from follow-up periods longer than 1 year are still scarce.
María Fernanda Guerra Veloz, María Belvis Jiménez, Teresa Valdes Delgado, Luisa Castro Laria, Belén Maldonado Pérez, Raúl Perea Amarillo, Vicente Merino Bohórquez, Ángel Caunedo Álvarez, Ángel Vilches Arenas, Federico Argüelles-Arias   +9 more
doaj   +1 more source

Stage‐Associated Microglial Subpopulations and Dynamics in Vascular Pathogenesis of Oxygen‐Induced Retinopathy

Cell Proliferation, EarlyView.
In the oxygen‐induced retinopathy (OIR) mouse model, two distinct microglial subpopulations play opposing roles: highly glycolytic microglia (HGM) promote neovascular formation via Pkm2, while Mrc1/CD206‐positive phagocytosis‐associated microglia (PAM) facilitate its regression.
Yuan Ma, Ziye Chen, Baoyi Liu, Wen Ding, Runping Duan, Kangjie Kong, Zhuojun Xu, Jizhu Li, Jiali Ru, Dianlei Guo, Xiaoyue Wei, Yaping Liu, Zhuangling Lin, Yang Meng, Yuan Liu, Lan Jiang, Zitong Chen, Rebiya Tuxun, Chinling Tsai, Chunqiao Liu, Tao Li   +20 more
wiley   +1 more source

The effectiveness and safety of infliximab compared with biosimilar CT-P13, in 3112 patients with ulcerative colitis. [PDF]

Aliment Pharmacol Ther, 2019
SummaryBackgroundCT‐P13, a biosimilar of the reference product infliximab, has been approved for the treatment of ulcerative colitis on the basis of the results of trials conducted in patients with spondyloarthritis and rheumatoid arthritis.AimTo compare the effectiveness and safety of CT‐P13 and the reference product in infliximab‐naive patients with ...
Meyer A, Rudant J, Drouin J, Coste J, Carbonnel F, Weill A.   +5 more
europepmc   +4 more sources

Exploring How Gerontological Nursing Telephone Support Can Assist Informal Caregivers of Older Adults at Hospital Discharge—A Qualitative Study

Journal of Clinical Nursing, EarlyView.
ABSTRACT Aim and Objective To explore how receiving gerontological nurse telephone support assisted caregivers of older adults to provide care after hospital discharge. Background Informal caregivers are vital to the recovery of older patients after hospital discharge, but often feel under‐prepared and unsupported.
Cheng Yen Loo, Susan Slatyer, Ami Kamdar, Trish Starling, Keith D. Hill, Laurie Grealish, Howard Lance, Anne‐Marie Hill   +7 more
wiley   +1 more source

Quantitative comparison of the neutralizing capacity, immunogenicity and cross-reactivity of anti-TNF-α biologicals and an Infliximab-biosimilar.

PLoS ONE, 2018
IntroductionTNF-α-neutralizing antibodies, such as infliximab (IFX) and adalimumab (ADA), are effective in the treatment of inflammatory bowel diseases (IBD), but they are expensive and become ineffective when patients develop anti-IFX or anti-ADA ...
D J Buurman, T Blokzijl, E A M Festen, B T Pham, K N Faber, E Brouwer, G Dijkstra   +6 more
doaj   +1 more source

Diagnostic and prognostic value of fecal, serum and endoscopic markers in inflammatory bowel disease and colorectal cancer [PDF]

, 2018
Background. The most important goals of the recent therapies of inflammatory bowel disease (IBD) are to induce and maintain clinical remission and mucosal healing (MH), which can be achieved with anti-TNF-α biological therapy.
Rutka Mariann
core  

Biosimilar infliximab (CT-P13) in the treatment of inflammatory bowel disease: A Norwegian observational study [PDF]

Expert Review of Gastroenterology & Hepatology, 2015
To assess the efficacy, tolerability, and safety of CT-P13 (Remsima(®)) in patients with Crohn's disease (CD) or ulcerative colitis (UC).This was a prospective observational study performed in a single center in Norway. Patients with CD (n = 46) or UC (n = 32) received CT-P13 (5 mg/kg) by intravenous infusion at weeks 0, 2, and 6.
Jørgen, Jahnsen, Trond Espen, Detlie, Simen, Vatn, Petr, Ricanek   +3 more
openaire   +2 more sources